← Leaderboards
Michael E. Johnson
University Of Illinois At Chicago
$23,655,611
Attributed
$24,254,113
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.4M · FY2005–15$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$31,937,391 · 9
By mechanism
U19$15,456,716 · 1
P01$9,381,510 · 2
U01$4,020,530 · 1
R56$1,517,021 · 1
R41$1,197,004 · 2
R01$339,120 · 1
Top collaborators
- Shahila Mehboob Christie2 shared
- Hyun Lee2 shared
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Hyunwoo Lee$2,832,266
- Abhijit A Date$4,064,660
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseDesignStructureBinding (Molecular Function)EnzymesInhibitor/AntagonistLeadDrug ResistanceResistanceBiologicalBiological AvailabilityScaffoldEnzyme Inhibitor DrugsEnzyme InhibitorsComputer SimulationScreening ProcedurePharmaceutical ChemistryAntiviral AgentsPeptide HydrolasesRoentgen RaysCytotoxicityMetabolicAnti-Bacterial AgentsAnimals
Grant awards (24)
Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors$300,000
R41 · FY2015 · AI · contact PI
Development of Novel S. aureus Antibiotics with Reduced Resistance Susceptibility$298,502
R41 · FY2015 · AI · contact PI
Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors$300,000
R41 · FY2014 · AI · contact PI
Development of Novel S. aureus Antibiotics with Reduced Resistance Susceptibility$298,502
R41 · FY2014 · AI · contact PI
Novel antiobiotic development for biodefense$1,991,637
U01 · FY2010 · AI · contact PI
Development of PLpro and 3CLpro Protease Inhibitors as Novel SARS Therapeutics$1,517,021
R56 · FY2010 · AI · contact PI
Novel antiobiotic development for biodefense$2,028,893
U01 · FY2009 · AI · contact PI
Novel Protease Inhibitors as SARS Therapeutics$1,553,610
P01 · FY2009 · AI · contact PI
Computational Design, Bioinformatics & Screening$357,946
P01 · FY2009 · AI · contact PI
Novel Protease Inhibitors as SARS Therapeutics$1,510,698
P01 · FY2008 · AI · contact PI
Computational Design, Bioinformatics & Screening$348,916
P01 · FY2008 · AI · contact PI
Novel Therapeutics for Bacillus anthracis$3,440,534
U19 · FY2007 · AI · contact PI
Novel Protease Inhibitors as SARS Therapeutics$1,497,577
P01 · FY2007 · AI · contact PI
Computational Design, Bioinformatics & Screening$342,837
P01 · FY2007 · AI · contact PI
CONFORMATIONAL CHANGES OF ENZYME GLUTAMATE RACEMASE BY SAXS & WAXS$25,490
P41 · FY2007 · RR · contact PI
Novel Therapeutics for Bacillus anthracis$3,440,090
U19 · FY2006 · AI · contact PI
Novel Protease Inhibitors as SARS Therapeutics$1,499,929
P01 · FY2006 · AI · contact PI
Computational Design, Bioinformatics & Screening$314,101
P01 · FY2006 · AI · contact PI
Novel Therapeutics for Bacillus anthracis$3,420,271
U19 · FY2005 · AI
Novel Protease Inhibitors as SARS Therapeutics$1,621,464
P01 · FY2005 · AI
Computational Design, Bioinformatics &Screening$334,432
P01 · FY2005 · AI
Novel Therapeutics for Bacillus anthracis$3,320,641
U19 · FY2004 · AI
Novel Therapeutics for Bacillus anthracis$1,835,180
U19 · FY2003 · AI
DEVELOPMENT OF SITE SPECIFIC ANTISICKLING AGENTS$339,120
R01 · FY2000 · HL